Details
Dr Feldman has broad business, medical and life-science research
experience. He obtained his medical degree in London, his PhD in
The Netherlands and has also worked at Harvard Medical School.
Dr Feldman held clinical and academic appointments at Imperial
College, London in Neonatal Infection. As a serial life-sciences
entrepreneur, he founded the UK vaccine company Microscience and
subsequently antimicrobial company Vmax. He then became the CEO
of the hepatitis C therapeutic company RioTech based in London
before establishing European operations for the New York based
drug development venture firm for Paramount Biosciences, LLC.
Subsequently, he went on to be Entrepreneur in Residence at
Imperial Innovations in London where he co-founded the spin-out
company Indigix. He then moved to New Zealand to join Pacific
Channel as Executive Director and subsequently founded Line 5,
the life-sciences consulting company.
Dr Feldman’s breadth of expertise spans therapeutics, devices, diagnostics and functional preparations in the field of human health. Through his varied career, Dr Feldman has obtained operational, businesses development, fundraising, product development, venture and governance expertise. He has a deep level of experience in presentations for fundraising and business development having both successfully raised funds from investors and worked in a venture firm. He has also successfully concluded licensing deals in Europe, USA, Australia, Russia and South Korea as well as engaging in business development activities in many other countries. Through Line 5, Dr Feldman is active in performing due diligence for investors, company troubleshooting, mentoring early stage businesses, engaged in strategic and business planning. He is currently a non-executive director of Canterbury Scientific Ltd.
Dr Feldman’s breadth of expertise spans therapeutics, devices, diagnostics and functional preparations in the field of human health. Through his varied career, Dr Feldman has obtained operational, businesses development, fundraising, product development, venture and governance expertise. He has a deep level of experience in presentations for fundraising and business development having both successfully raised funds from investors and worked in a venture firm. He has also successfully concluded licensing deals in Europe, USA, Australia, Russia and South Korea as well as engaging in business development activities in many other countries. Through Line 5, Dr Feldman is active in performing due diligence for investors, company troubleshooting, mentoring early stage businesses, engaged in strategic and business planning. He is currently a non-executive director of Canterbury Scientific Ltd.